Handelsbanken Fonder AB Purchases Shares of 19,400 Structure Therapeutics Inc. Sponsored ADR $GPCR

Handelsbanken Fonder AB purchased a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 19,400 shares of the company’s stock, valued at approximately $1,041,000.

Several other large investors have also made changes to their positions in GPCR. CWM LLC boosted its stake in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares during the period. Sterling Capital Management LLC acquired a new position in shares of Structure Therapeutics during the first quarter worth approximately $28,000. State of Wyoming acquired a new position in shares of Structure Therapeutics during the second quarter worth approximately $28,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Structure Therapeutics in the fourth quarter valued at approximately $127,000. Finally, Assetmark Inc. boosted its position in shares of Structure Therapeutics by 21.4% in the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after acquiring an additional 449 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Trading Up 1.1%

GPCR opened at $54.13 on Thursday. The stock’s 50 day simple moving average is $50.03 and its 200-day simple moving average is $51.89. The stock has a market cap of $3.77 billion, a PE ratio of -54.13 and a beta of -1.43. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $18.26 and a 1 year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Citizens Jmp reduced their price target on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating for the company in a report on Friday, August 7th. Wall Street Zen upgraded shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Finally, Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a research report on Friday, August 7th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.91.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.